P I Industries Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Soft year, cautious FY26 guide: Revenue growth guided at just mid single digits for FY26, as global agrochemical headwinds, price softness, and climatic uncertainty persist; management expects a second-half recovery.
• Margins held, but investments weigh: Consolidated EBITDA margin was 25.6% in Q4 and 27.4% for the full year, while the company reaffirmed a ~25% long-term sustainable band, absorbing the cost of building new pharma and biologicals platforms.
• The pharma bet is still a cost centre: The pharma CRDMO business posted an EBITDA loss of ₹180–₹190 crore in FY25 and will not break even in FY26; management sees positive trends only over FY26–FY28.
• Biologicals get a number and a timeline: The newly acquired Plant Health Care platform puts a 5x revenue target on biologicals, from ~₹250 crore to ₹1,000–₹1,200 crore, over the next five years.
• What to watch next quarter: Whether the promised H2 recovery in CSM exports materialises, the pace of new pharma customer additions, and any progress on the first country registration for the NCE PIOXANILIPROLE.

Demand Environment & Revenue Outlook

• Agchem exports under pressure: CSM exports grew ~5% YoY, driven entirely by new products commercialised over the last few years, which grew ~31%. Legacy product pricing softened as input cost declines were passed through to customers, a structural feature of the CSM model that compresses reported revenue growth.
• Domestic brands the bright spot: The domestic branded business grew ~21% YoY in Q4, led by product mix and a crop solutions approach. Biologicals within the domestic portfolio grew 20% over the prior year.
• New product momentum is seasonal: New molecules grew ~40%+ in Q2 and Q3 but only ~20%+ in the remaining two quarters, a pattern management calls normal for the industry. The company commercialised 15 products in the last three years and expects a similar pipeline in FY26.
• The H2 bet: Management expects broader sentiments and export growth to improve in the second half of FY26, citing new product launches. The base for CSM exports is now high after growing 20–25% for the last 3–4 years, so a catch-up in growth momentum is expected from H2.
• Pharma pipeline building, not converting yet: The pharma business added early and late development pipeline projects in high single digits and on-boarded two new big pharma customers. The goal in FY26 is to add another two or three, building a base for consistent revenue, but no order book numbers were disclosed.

Singhal: "Yes, very clearly over the next FY26, FY27, FY28, we should see the positive trends of this business very clearly."

Margin Structure & Investment Logic

• Q4 margin walk: Consolidated EBITDA grew 3% to 25.6%, supported by good product mix and tight overhead management, despite development expenses in pharma and PHC. Full-year consolidated EBITDA grew 8% to 27.4%.
• The ~25% floor is deliberate: Management reaffirmed ~25% as a long-term sustainable EBITDA margin, explicitly factoring in the cost of building global organisations in biologicals and pharma, which operate on a different cost structure.
• Pharma losses are the main drag: The pharma business posted an EBITDA loss of ₹180–₹190 crore in FY25, with one-offs including a doubtful debt provision for a specific customer and other costs that are not expected to recur. Pharma EBITDA breakeven will take time over the next few years and is not expected in FY26.
• Gross margin guided at 50–52% for FY26, depending on final product mix.
• Tax rate reset: The effective tax rate rose to 22.5% in FY25 from 11.2% last year, and is expected to remain in the 22–23% range for the next 2–3 years, a structural headwind to profit growth.

Singhal: "At the same time, I think just to appreciate that the company is investing hugely to build a global footprint in biologicals and in pharma and cost of running global organizations from a different cost structure."

New Business Platforms: Pharma, Biologicals & Beyond

• Pharma CRDMO: The company is taking a step-by-step approach, upgrading and adding to its asset base across geographies. It on-boarded two new big pharma customers in FY25 and targets another two or three in FY26, aiming for a sound base of big pharma for consistent revenue and biotech for better margins.
• Biologicals get a hard target: The acquisition of Plant Health Care, which specialises in peptides, positions PI as a platform technology-based biologicals company. Management set an aspirational target to grow biologicals revenue 5x in five years, from ~₹250 crore currently to ₹1,000–₹1,200 crore, and to expand the play from domestic to global over that period.
• Electronic chemicals: The company is actively positioning to capture value in this new vertical, alongside pharma CRDMO and biologicals, though no specific numbers were disclosed.
• NCE PIOXANILIPROLE: PI's first novel chemical entity from India is in the midst of Phase 3 trials. The company is evaluating partnerships globally and developing regulatory data, with an objective to commercialise in the very first country in the next couple of years. India is the priority first market, with work underway in 2–3 countries using a partner's application.

Singhal: "We have been so far looking at biological play at domestics level but for the next 5 years, it will become a global play."

Capital Allocation & Balance Sheet

• CAPEX stepping up: FY26 CAPEX is guided at ₹800–₹900 crore, with approximately ₹100 crore allocated to PIHS (pharma) and the balance to agrochemical manufacturing. Two multi-product plants are under construction, with one expected to commission this year and the next at the beginning of March next year.
• Balance sheet strength: Net worth increased to ₹10,157 crore, with a net cash balance of ₹4,092.6 crore, providing ample capacity to fund the investment cycle.
• Working capital normalising: Trade working capital increased to 73 days, but inventory days reduced from 62 to 45. Management expects working capital to settle around 65–70 days. Contract assets rose to ₹430 crore from ₹150–₹160 crore last year, which management attributed to standard industry practice for goods produced for specific customers but shipped after the cutoff date.
• Asset turns: Management targets a sustainable asset turn of 2.2x–2.5x, expecting to manage this better on average over a three-year period.

Guidance & Commitments

Key Metrics